# Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

> **NCT05123209** · PHASE1 · UNKNOWN · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** IM83 CAR-T cells
- **COMBINATION_PRODUCT:** The second-line treatment of liver cancer

## Key facts

- **NCT ID:** NCT05123209
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-24
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2021-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123209, "Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05123209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*